Laronde Raises $440M in Series B Financing

30 Aug, 2021

Laronde Raises $440M in Series B Financing
Photo by Dose Media on Unsplash

– Laronde is a Cambridge, Mass.-based company advancing Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body.
– The company raised $440m in Series B financing.
– The round was led by Flagship Pioneering, with participation from T. Rowe Price Associates, Inc., Invus, Canada Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company, funds and accounts managed by BlackRock, and Federated Hermes Kaufmann Funds, among others.
– The new investment will be used to advance the development of the company’s eRNA platform and a broad pipeline of programs across a number of therapeutic categories.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: